MARKET

AZN

AZN

Astrazeneca Plc
NASDAQ
64.79
+0.20
+0.31%
After Hours: 64.81 +0.02 +0.03% 19:50 12/01 EST
OPEN
64.59
PREV CLOSE
64.59
HIGH
65.06
LOW
64.37
VOLUME
3.62M
TURNOVER
0
52 WEEK HIGH
76.56
52 WEEK LOW
61.22
MARKET CAP
200.84B
P/E (TTM)
34.28
1D
5D
1M
3M
1Y
5Y
Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments
Tang capital offers $465m for lianbio plus 80% of any licenses/divestments. Merck’s keytruda announced it will set the price for its pd-1 drug in the us. Lian bio received a $465 million buyout offer from tang capital management.
Seeking Alpha · 1d ago
Astrazeneca Plc: Report of foreign issuer
Press release · 2d ago
EU regulators seeking more info on GLP-1s and suicidal thoughts: report
European regulators are looking into whether certain diabetes and weight-loss drugs may trigger suicidal thoughts in some users. The european medicines agency began a review in july after receiving at least 170 reports. Novo nordisk and eli lilly are among drugmakers under investigation for possible link.
Seeking Alpha · 2d ago
Pfizer hits new 52-week low after weight loss setback
Pfizer shares hit new 52-week low after weight loss setback. Pfizer's twice-daily oral weight loss candidate danuglipron will not reach late-stage development. The company's first obesity candidate, lotiglipron, met a similar fate in june.
Seeking Alpha · 2d ago
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
Ema will request further clarifications from drugmakers of glp-1 receptor agonists for diabetes and weight loss. Novo nordisk's popular therapies ozempic and wegovy have been linked to suicidal thoughts. Ema received reports of two cases of suicidal thoughts linked to the drugs in july.
Benzinga · 2d ago
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
NASDAQ · 2d ago
Health Care Sector Update for 12/01/2023: PFE, BIOR, AZN, XLV, IBB
NASDAQ · 2d ago
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
Benzinga · 2d ago
More
About AZN
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, the Americas and Asia, Africa and Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.

Webull offers AstraZeneca plc (ADR) stock information, including NASDAQ: AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.